RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama

DOI: 10.1007/s00280-022-04428-0
Published: 2022-04-20
Container: Cancer Chemotherapy and Pharmacology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00280-022-04428-0,
  title = {RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment},
  author = {Mototsugu Oya and Shuichi Kaneko and Tsuneo Imai and Toshiaki Tsujino and Toshiyuki Sunaya and Yutaka Okayama},
  year = {2022},
  journal = {Cancer Chemotherapy and Pharmacology},
  doi = {10.1007/s00280-022-04428-0},
  url = {https://doi.org/10.1007/s00280-022-04428-0}
}

RIS

TY  - JOUR
TI  - RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
AU  - Mototsugu Oya
AU  - Shuichi Kaneko
AU  - Tsuneo Imai
AU  - Toshiaki Tsujino
AU  - Toshiyuki Sunaya
AU  - Yutaka Okayama
PY  - 2022
JO  - Cancer Chemotherapy and Pharmacology
DO  - 10.1007/s00280-022-04428-0
UR  - https://doi.org/10.1007/s00280-022-04428-0
ER  -

APA

Oya, M., Kaneko, S., Imai, T., Tsujino, T., Sunaya, T., & Okayama, Y. (2022). RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-022-04428-0

Source records

crossref · retrieved 2026-09-25T13:07:26.963Z